Search results
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 3 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 9 months agoEditas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript August 2, 2023 Editas Medicine,...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 1 year agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Is Editas Medicine Stock a Buy Now?
Motley Fool· 10 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool via Yahoo Finance· 4 months agoInvesting in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but...
Will Editas Medicine (NASDAQ:EDIT) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ...
GuruFocus.com via Yahoo Finance· 6 months agoEditas Medicine Inc (NASDAQ:EDIT) reports a net loss of $45.0 million for Q3 2023, down from $55.7...
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) sits at the bleeding edge of biotech's hottest field, gene editing to...
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Institutions' substantial holdings in Editas Medicine implies that they have...